Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure

Completed · Phase 4 · Has a placebo group

Conditions studied: Symptomatic Uterine Fibroids and Adenomyosis

In brief

The uterine fibroid embolization (UFE) procedure is a treatment option for abnormal heavy menstrual bleeding and/or bulk symptoms associated with uterine fibroids and adenomyosis. Post UFE procedural pain and nausea are expected events. These symptoms are treated with current standard of care medications, including opiates. Intra procedure pain medications include midazolam, fentanyl and hydromorphone. Some centers include nonsteroidal anti-inflammatory medications (NSAIDS), including oral ibuprofen and IV ketorolac. Post procedural pain control is centered on a hydromorphone patient-controlled analgesia (PCA) infusion pump, as well as a NSAID regimen. Intra procedure and post procedure nausea control medications include a transcutaneous scopolamine patch and IV anti-nausea medications such as ondansetron and prochlorperazine. This study is being conducted to compare two new medications for pain, IV ibuprofen and IV acetaminophen, administered for 24 hours following UFE. The primary safety objective of non-inferiority will be met and the primary efficacy objective of superiority, decreased pain and nausea, will be accessed when compared to current standard of care regimens. This is a 4 arm, double blind, randomized, controlled study. All patients will receive standard of care baseline pain medications, including IV midazolam, fentanyl and hydromorphone intra procedure, followed by a hydromorphone PCA infusion pump post procedure. The 4 arms will include: \[ Arm 1\] IV ibuprofen/IV placebo, \[Arm 2\] IV acetaminophen/IV placebo, \[Arm 3\] IV ibuprofen/IV acetaminophen, and \[arm 4\] IV placebo/IV placebo. These medications will be given during the procedure and extended over a 24 hour stay. Arm 4 (IV placebo/IV placebo) would replicate current standard of care, and therefore will include IV push (IVP) ketorolac, which would be given at the end of the procedure and be continued every 6 hours for the 24 hour stay. An IVP of saline will be given as a control every 6 hours for the 24 hour stay to arms 1, 2 and 3. Pain and nausea will be measured at intervals prior to the procedure, throughout the stay and at 2 weeks post procedure.

Key facts

Study ID

NCT02227316

Run by

University of California, Los Angeles

People needed

40

Starts

2014-08-01

Expected to finish

2016-09-01

Last updated by the study team

2018-06-08

Who can join

Age: 21 and older, up to 60. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients being considered for UFE including bleeding and/or bulk symptoms.
• Women of all ethnicities
• Ages 21-60

You may not qualify if…

• Patients with current malignancy receiving treatment
• Women who are pregnant
• Cognitive impairment
• Clinically significant kidney disease
• Clinically significant liver disease
• Any recent history of gastrointestinal bleed or ulcer
• Weight less than 50 kg (medication dosing requirements change below 50 kg)
• Women with a body mass index (BMI) equal to or over 50 (with other co-morbidities)
• Known allergy or hypersensitivity to NSAID or acetaminophen
• Administration of acetaminophen, NSAID, narcotic or any other analgesic less than 6 hours prior to UFE procedure
• Any chronic use of pain medications including acetaminophen, NSAID, narcotic or analgesic
• Patients who cannot or choose not to consent to participate in the study

Where it is running

• Ronald Reagan UCLA Medical Center — Los Angeles, California, United States
• Santa Monica/UCLA Medical Center and Orthopaedic Hospital — Santa Monica, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.